The UK and US have hammered out a landmark commercial pact that will maintain no import taxes on UK pharmaceutical shipments being sold in the American market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has pledged to increase spending on medicines through the NHS. This pledge secures that duties on these vital exports will be held at zero for a period of 36 months.
This deal is in response to earlier statements to significantly raise duties on patented drug products, with figures discussed up to one hundred percent.
"This agreement with the UK strengthens the global environment for innovative medicines and introduces long-overdue balance to U.S.–U.K. drug exports," a statement said.
Economic Importance
Pharmaceuticals represent one of the UK's largest goods shipped to the America, which is by far the primary market for leading UK drugmakers.
Trade data show that in the 12 months to the end of last September, the UK shipped pharmaceutical products valued at over eleven billion pounds to the US. This amount accounted for nearly one-fifth of all goods exports in that span.
"This agreement protects work, increases investment and facilitates the UK to emerge as a international leader for medical research," the Business and Trade Secretary commented.
Detailed British Pledges
The pact involves several key commitments from the United Kingdom:
- Revised Affordability Limit: The UK will raise the price threshold at which it judges new treatments to be prohibitively costly by 25%.
- Increased NHS Spending: There is a aim to raise overall NHS spending on drugs from 0.3 percent of GDP to 0.6 percent over the next decade.
- Payback Limit: The sum drug companies must pay back to the NHS to control costs will be limited at 15%. Last year, repayments topped twenty percent.
Broader Context
This agreement takes place against a ongoing row between the sector and the UK government over drug pricing and NHS adoption.
The disagreement were exacerbated by arguments that US patients were paying several times more for the same drugs than patients in the Britain and the EU.
In recent months, several major drug company projects in the UK have been delayed or scrapped, while substantial expansions have been pledged toward projects in the United States.
One official stated that the NHS had to spend more on medicines, noting that its budget allocation on drugs had shrunk as a share of its overall budget over the last ten years.
